| Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths | 09/16 13:05 | investors.com |
| iTeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session | 09/16 08:44 | benzinga.com |
| iTeos Therapeutics: ESMO Data Showing Signs Of A Real Win For TIGIT | 09/15 03:37 | seekingalpha.com |
| iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients | 09/14 02:30 | globenewswire.com |
| iTeos to Participate in Upcoming Investor Conferences | 08/28 16:30 | globenewswire.com |
| iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024 | 08/20 08:30 | globenewswire.com |
| ITeos Therapeutics, Inc. (ITOS) Reports Q2 Loss, Tops Revenue Estimates | 08/08 09:21 | zacks.com |
| iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer | 08/05 07:00 | globenewswire.com |
| iTeos Therapeutics: Rippling Waves Of TIGIT Pessimism | 07/08 21:00 | seekingalpha.com |
| iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK | 07/08 07:00 | globenewswire.com |